Late Electrocardiographic Changes in Patients With New-Onset Left Bundle Branch Block Following Transcatheter Aortic Valve Implantation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 07 10 2019
revised: 20 11 2019
accepted: 22 11 2019
pubmed: 1 1 2020
medline: 1 7 2020
entrez: 1 1 2020
Statut: ppublish

Résumé

This study sought to determine, in patients with new-onset persistent left bundle branch block (NOP-LBBB) after transcatheter aortic valve implantation (TAVI), the incidence and factors associated with (i) LBBB recovery and (ii) permanent pacemaker implantation (PPI) at 1-year follow-up. This was a multicenter study including 153 patients (mean age: 81 ± 5 years, 56% of women) with NOP-LBBB post-TAVI (balloon-expandable valve in 112 patients). Delta PR (ΔPR) and delta QRS (ΔQRS) were defined as the difference in PR and QRS length between baseline and hospital discharge ECG, and the relative ΔPR and ΔQRS as absolute ΔPR and ΔQRS divided by baseline PR and QRS length, respectively. The patients had a clinical visit and 12-lead ECG at 1-year follow-up. LBBB recovery was observed in 50 patients (33%), and 14 patients (9%) had advanced conduction disturbances requiring PPI during the follow-up period. No clinical or ECG variables were associated with LBBB recovery, including prosthesis type (self- or balloon-expandable valve, p = 0.563), QRS width at baseline/discharge or absolute/relative ΔQRS (p >0.10 for all). The presence of atrial fibrillation at baseline (0.026), a longer PR interval at discharge (0.009), and a longer absolute and relative ΔPR (p = 0.002 and p = 0.004, respectively) were associated with an increased risk of PPI at 1-year follow-up. In conclusion, NOP-LBBB post-TAVI resolved in one-third of patients at 1-year follow-up, but no clinical or ECG variables were associated with LBBB recovery. Conversely, a nonsinus rhythm at baseline and a longer ΔPR were associated with an increased risk of PPI within the year after TAVI.

Identifiants

pubmed: 31889524
pii: S0002-9149(19)31345-1
doi: 10.1016/j.amjcard.2019.11.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

795-802

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Laurent Faroux (L)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Guillem Muntané-Carol (G)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Marina Urena (M)

Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

Luis Nombela-Franco (L)

Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Ignacio Amat-Santos (I)

Hospital Universitario de Valladolid, Valladolid, Spain.

Neal Kleiman (N)

Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.

Antonio Munoz-Garcia (A)

Hospital Virgen de la Victoria, Malaga, Spain.

Felipe Atienza (F)

Hospital General Universitario Gregorio Maranon, Madrid, Spain.

Vicenç Serra (V)

Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Marc W Deyell (MW)

St. Paul's Hospital, Vancouver, British Columbia, Canada.

Gabriela Veiga-Fernandez (G)

Hospital Universitario Marques de Valdecilla, Santander, Spain.

Jean-Bernard Masson (JB)

Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada.

Victoria Canadas-Godoy (V)

Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Dominique Himbert (D)

Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

Quentin Fischer (Q)

Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

Javier Castrodeza (J)

Hospital Universitario de Valladolid, Valladolid, Spain.

Jaime Elizaga (J)

Hospital General Universitario Gregorio Maranon, Madrid, Spain.

Jaume Francisco Pascual (JF)

Hospital Universitari Vall d'Hebron, Barcelona, Spain.

John G Webb (JG)

St. Paul's Hospital, Vancouver, British Columbia, Canada.

Jose M de la Torre (JM)

Hospital Universitario Marques de Valdecilla, Santander, Spain.

Lluis Asmarats (L)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Emilie Pelletier-Beaumont (E)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Marcel Alméndarez (M)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Thomas Couture (T)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Francois Philippon (F)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodes-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH